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Hyperfibrinolysis may occur due to systemic inflammation or hepatic injury that occurs during 
liver resection.  Tranexamic Acid (TXA) is an antifibrinolytic agent that decreases bleeding in 
various settings, but has not been well studied in patients undergoing liver resection.   
Methods 
In this prospective, phase II trial, 18 patients undergoing major liver resection were sequentially 
assigned to one of three cohorts: (1) Control (no TXA); (2) TXA Dose I- 1 g bolus followed by 1 g 
infusion over 8 hours; (3) TXA Dose II- 1 g bolus followed by 10 mg/kg/hr until the end of 
surgery.  Serial blood samples were collected for thromboelastography (TEG), coagulation 
components and TXA concentration.  
Results 
No abnormalities in hemostatic function were identified on TEG. PAP complex levels increased 
to peak at 1106 ug/L (normal 0-512 ug/L) following parenchymal transection, then decreased to 
baseline by the morning following surgery.  TXA reached stable, therapeutic concentrations 
early in both dosing regimens.  There were no differences between patients based on TXA.   
Conclusions 
There is no thromboelastographic evidence of hyperfibrinolysis in patients undergoing major 
liver resection.  TXA does not influence the change in systemic fibrinolysis; it may reduce 
bleeding through a different mechanism of action.    
Keywords: Blood Transfusion, Fibrinolysis, Hemostasis, Hepatectomy, Tranexamic Acid 
Registered with ClinicalTrials.gov: NCT01651182  
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INTRODUCTION 
Liver resection is the optimal treatment for patients with primary or metastatic liver 
malignancies, benign liver tumors, and some biliary diseases.1-5 Despite many technical 
advances, intraoperative bleeding remains a problem during liver resection with 30-40% of 
patients receiving perioperative blood transfusions.6-8 Blood transfusion carries several risks, 
including transfusion-transmitted viruses, transfusion-related acute lung injury, transfusion-
associated circulatory overload, acute hemolytic transfusion reactions, bacterial contamination 
and severe allergic reactions.9  In addition, bleeding and blood transfusion are risk factors for 
postoperative morbidity and in some reports, long-term cancer recurrence.6,10-22   Furthermore, 
blood products are sometimes scarce and associated with appreciable expense.  Thus, there is 
compelling rationale to reduce blood loss and blood transfusion as much as possible in patients 
undergoing liver resection. 
Hemostatic function is determined by the interaction of the vascular wall, platelets, 
coagulation factors, and fibrinolytic function.7,23,24 The hemostatic system may be abnormal in 
patients who have compromised liver function and this may contribute to excessive bleeding 
during liver surgery.  In particular, primary hyperfibrinolysis may occur as a result of the 
systemic inflammatory effect of surgery or due to hepatic injury that occurs during liver 
surgery.  Hyperfibrinolysis may be inhibited by the administration of antifibrinolytic agents 
including plasmin inhibitors (aprotinin) and plasminogen inhibitors (lysine analogues - 
tranexamic acid (TXA) and episilon aminocaproic acid (EACA)). Although aprotinin appears to be 
effective at reducing bleeding, its use has been associated with an increased risk of death and 
renal compromise when compared to the lysine analogs.25,26  
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TXA decreases bleeding in various settings including multisystem trauma, orthopedic 
surgery, spine surgery, cardiopulmonary bypass, and liver transplantation.7,27-31  It has not been 
well studied in patients undergoing liver resection, and it is rarely used in that setting.32,33 Our 
objectives were to characterize the impact of liver resection on systemic fibrinolysis, and to 
define the impact of TXA at two different doses on fibrinolysis. 
 
METHODS 
We conducted a prospective, open label, phase II trial examining the impact of TXA at 
two doses on fibrinolysis during major liver resection.  The protocol was approved by the 
Sunnybrook Health Sciences Centre Research Ethics Board and registered with ClinicalTrials.gov 
(NCT01651182). 
Patient Eligibility 
Patients over the age of 18 undergoing anticipated open or laparoscopic major liver 
resection (greater than two segments) were approached and invited to participate in the trial.  
Patients were excluded if they were scheduled for hepatectomy associated with vascular or 
biliary reconstruction, had a platelet count less than 100,000 x 109/L, severe anemia 
(hemoglobin level less than 90 g/L), documented arterial or venous thrombosis in the past 
three months, known disseminated intravascular coagulation, severe renal insufficiency (CrCl < 
30 mL/min), history of seizure disorder, hypersensitivity to TXA or any of the ingredients, were 
pregnant or lactating, unable to receive blood products, had received chemotherapy within 4 
weeks of scheduled operation, were taking anticoagulants, direct thrombin inhibitors or 
thrombolytic therapy within the last week, or were previously enrolled in this study.  Patients 
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were screened in the surgical clinic at the time of surgical consent and provided a separate 
consent to participate in this trial. 
Interventions 
Cohorts of 6 subjects were enrolled sequentially to one of the three regimens: (1) 
Control (no TXA); (2) TXA Dose I - 1 g bolus followed by 1 g infusion over 8 hours initiated 15 
minutes after the bolus dose; and (3) TXA Dose II: -1 g bolus followed by 10 mg/kg/hr initiated 
15 minutes after the bolus dose until the end of surgery.   Dose I was selected based on the 
CRASH-2 trial, in which 20,000 trauma patients worldwide were randomly assigned to TXA or 
placebo.27  This dose was effective at reducing death due to bleeding and was not associated 
with increased adverse events.  The higher dose, Dose II, is more frequently used in liver 
transplant surgery, with no increase in thrombosis, reoperation or mortality in this setting.34 
General anaesthesia and liver resection proceeded according to standard institutional 
practices with no other modifications for the purposes of this trial.  Clinicians were not 
permitted to utilize other systemically administered antifibrinolytic agents. All patients had a 
central line with the central venous pressure (CVP) maintained as low as possible during 
anaesthesia.35-37  Liver transection was accomplished using the Kelly-crush technique with  
portal inflow clamping (the Pringle maneuver) at the surgeons’ discretion.  Transfusion of blood 
products (red blood cells, fresh frozen plasma, platelets, or cryoprecipitate) was guided by a 
standardized restrictive protocol. Red blood cells were transfused for Hgb < 70 g/L; or Hgb 70-
90 g/L based on medical judgment with an indication provided by the transfusing clinician 
(coronary ischemia, hemodynamic instability, ongoing blood loss, etc). Red blood cells were 
transfused one unit a time in non-bleeding patients. Fresh frozen plasma was transfused for INR 
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> 1.5 with clinically active bleeding. Platelets were transfused only if the patient was clinically 
bleeding with platelet count < 50 x 109/L and cryoprecipitate only if patient was bleeding with 
fibrinogen < 1.0 g/L. 
Outcomes 
Routine clinical data were collected including patient demographics, extent of liver 
resection, intraoperative blood loss, transfusions, and postoperative complications until 
discharge. 
Blood samples were collected at four time points to determine the extent of fibrinolysis: 
(1) baseline – immediately after induction; (2) after liver mobilization, prior to transection; (3) 
after liver transection; and (4) post-operatively, 24 hours following induction.   At each of these 
times two 5 ml samples of arterial blood were collected into standard citrated blood tubes.  The 
following laboratory parameters were measured: INR, PTT, fibrinogen, and plasmin-antiplasmin 
(PAP) complex.  PAP is a relatively stable complex of plasmin (the key enzyme of the fibrinolytic 
system) and its inhibitor α2-antiplasmin.  The plasma PAP concentration is thus a measure of 
the current activity of the fibrinolytic system. Expected normal values for PAP complex levels 
are 0–514 ug/L (2.5–97.5% percentiles).   
A 2 mL sample was collected from each patient for thromboelastography (TEG) 
assessment, which assesses the viscoelastic properties of whole blood clotting under low shear 
conditions. TEG samples were processed within 1 h of blood draw at 37 °C using a Rotational 
Thromboelastometry (TEG) delta instrument (TEM International, Munich, Germany). The 
methodology and the parameters of TEG have been described previously in detail38.  Two 
separate TEG assays were performed for each patient: (1) the EXTEM assay activates 
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haemostasis via the physiological activator tissue factor and is a screening test for extrinsic 
haemostatic function; (2) the FIBTEM assay eliminates the platelet contribution of clot 
formation by inhibiting the platelets irreversibly with cytochalasin D.  A comparison of EXTEM 
and FIBTEM allows for the detection of fibrinogen deficiency or fibrin polymerization disorders. 
Blood samples were collected in all patients for pharmacokinetic analysis at the 
following times: baseline (immediately prior to drug bolus), during drug infusion at time 0, 30, 
60, and every 120 min after initiation of the infusion, and during the drug elimination phase 
after discontinuation of drug infusion at time 0, 4, and 24 hours.   Blood samples were collected 
in standard 2.5 ml citrated tubes (Vacutainer, Becton Dickson, Franklin Lakes, NJ, USA), 
centrifuged and the plasma supernatant stored at -70°C within 6 hours of sampling.  TXA 
concentration was measured using solid phase microextraction techniques and Tandem liquid 
chromatography-mass spectrometry as previously described39,40. 
Statistical Analysis 
Descriptive statistics were used to summarize patient demographics and clinical 
outcomes. Categorical variables were reported as absolute values (N) and frequencies (%) and 
compared between groups using Fisher’s exact test (F-E). Continuous variables were reported 
as medians and interquartile ranges (IQRs) and Kruskal-Wallis (K-W) testing was used to detect 
statistically significant differences between the three groups. Non-linear mixed effects 
modeling explored the extent of fibrinolysis that occurs during liver resection, the impact of 
TXA on fibrinolysis, and the impact of TXA dosing regimen on TXA plasma concentration.    
The analytical plan was to select the most appropriate dose of TXA for future study 
based on the inhibition of hyperfibrinolysis using TEG or PAP complexes.  In the absence of 
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differences in either of these measures, the dose was selected as the minimum required to 
achieve a stable plasma TXA concentration of 10 mcg/ml; the concentration demonstrated in 
vitro to be required to completely inhibit fibrinolysis.  The sample size calculation was based on 
the pharmacokinetic modeling; with six patients in each group the pharmacokinetic profile of 
both regimens could be confidently differentiated using pharmacokinetic computer modeling 
(NONEM, GloboMax LLC, Hanover, MD). 
 
RESULTS 
 The majority of patients (16 of 18) underwent liver resection for colorectal cancer liver 
metastases, with only one patient diagnosed with hepatocellular carcinoma and one with 
cholangiocarcinoma (Table 1).  Operations were extensive; including extended right 
hepatectomy (5), right hepatectomy (4), left hepatectomy (1), and a variety of non-anatomic 
resections encompassing greater than two segments.  Median operative time was 291 minutes, 
including 67 minutes of parenchymal transection time.  Surgeons used intermittent inflow 
occlusion (Pringle maneuver) in the majority of cases (15). 
 Clinical outcomes were favorable, with no mortalities and only one patient receiving red 
blood transfusion, while no patients received other blood products (Table 2).  There were no 
major complications.  Notably, there were no thromboembolic events or seizures noted during 
the study period.  Median length of stay was 5 days with a range of 3-18 days.  Two patients 
were readmitted after discharge, neither with bleeding or thromboembolic events. 
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 TEG analysis revealed normal whole blood clotting parameters with no evidence of 
hyperfibrinolysis, and no differences between control and TXA treatment groups (Supplemental 
Table).   
 INR increased significantly in patients by the end of parenchymal transection, and 
continued to rise by the morning of post-operative day 1 (POD1) (Figure 1).  Fibrinogen levels 
decreased steadily during operation, reaching a trough of 2.77 ± 0.71 g/L after parenchymal 
division then increasing by the morning of POD1, although they did not return to baseline 
(Figure 2).  PAP complex levels mirrored this trend, increasing steadily to peak at more than 
twice normal (1106 ± 407 µg/L) following parenchymal transection then decreasing by the 
following morning (Figure 3).  There were no differences noted in any of these measurements 
in patients treated with TXA at either dose.   
  Plasma TXA concentration increased rapidly immediately following the bolus to peak at 
204 ± 36 µg/mL.  After approximately one hour during TXA infusion, the concentration reached 
a steady concentration of 37 ± 3 µg/mL in the Dose I group and 70 ± 12 µg/mL in the Dose II 
group (Figure 4).  All TXA was eliminated by 24 hours following surgery. 
 
DISCUSSION 
 This trial examining hemostatic function during major liver resection demonstrated no 
evidence of hyperfibrinolysis by thromboelastography.  However, fibrinogen levels decreased 
and PAP, a marker of fibrinolysis, increased modestly during liver resection.  The use of TXA 
employing the dose used in the CRASH-2 study or the dose routinely used in liver 
transplantation had no detectable impact of fibrinogen levels or degradation.  Importantly, the 
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serum concentration of TXA was maintained throughout the perioperative period at 
concentration in excess of 10 mcg/ml; the concentration demonstrated in vitro to be required 
to completely inhibit fibrinolysis.   
Liver resection remains a major undertaking, with hepatic dysfunction combined with a 
profound systemic inflammatory response.  These two factors have the potential to 
substantially alter the systemic hemostatic function through a number of mechanisms, 
potentially including activation of hyperfibrinolysis.  Conventional laboratory measures of 
hemostatic function including INR and PTT are frequently elevated following major liver 
resection due to impaired hepatic synthetic function, and are not accurate measures of 
hemostatic function in this setting.  Furthermore, elevations in INR typically occur 24-48 hours 
following resection, whereas the majority of bleeding (and hence the opportunity for 
intervention) generally occurs intraoperatively.  In this study, INR was increased slightly 24 
hours following liver resection. Similarly, although fibrinogen levels decreased slightly during 
the course of hepatic transection, they are not sensitive enough to be relied upon for 
assessment of fibrinolytic function during major surgery.  
 Thromboelastometry has been studied in a number of settings where hyperfibrinolysis 
may occur, including multisystem trauma41.  A major advantage of TEG is its ability to provide 
real-time information regarding a patient’s hemostatic function.  However, massive near-fatal 
trauma is required to produce detectable changes in TEG, so it may not be sensitive enough to 
identify patients undergoing elective surgery with moderate hyperfibrinolysis who may benefit 
from antifibrinolytic therapy42.  In this study of patients undergoing major liver resection, TEG 
failed to identify any abnormalities in fibrinolytic function. 
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 In contrast, PAP complex levels may be elevated in patients with modest, but clinically 
significant hyperfibrinolysis.  In one study of patients with multisystem trauma, PAP complex 
levels were significantly elevated in 57% of patients with moderate or severe injuries, while TEG 
detected abnormalities in only 5% of patients42.  TEG detected clot lysis only when PAP complex 
levels were increased to 30 times normal.  Furthermore, PAP complex levels were 
independently associated with need for red blood cell transfusion, ventilator-free days, length 
of hospitalization, and 28-day mortality.  In our study, PAP complex levels increased modestly 
by the end of transection.  PAP complex levels had returned to baseline by the morning 
following surgery, indicating that the fibrinolytic activity is transient.   
 The transient fibrinolysis that occurs around the time of liver resection presents a 
potential opportunity to intervene and improve hemostatic function, thereby reducing blood 
loss and transfusion.  TXA has been well studied in various settings including multisystem 
trauma, orthopedic surgery, spine surgery, cardiopulmonary bypass, and liver 
transplantation.7,27-31  The most compelling evidence of the effectiveness of TXA comes from 
the large multicentred, multi-national CRASH-2 trial.27  This prospective randomized controlled 
trial included more than 20,000 patients with multisystem trauma in 40 countries. Patients 
randomized to receive TXA within one hour of trauma had a 32% reduction in death due to 
bleeding compared to placebo.   
In a recent meta-analysis of 95 surgical randomized controlled trials (N=7838 patients), 
TXA reduced the probability of receiving a blood transfusion by one third (risk ratio 0.62, 95% 
confidence interval 0.58 to 0.65; P<0.001).43 The majority of these trials were in cardiac and 
orthopaedic surgery however, where the mechanism of bleeding is significantly different than 
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abdominal surgery.  Four small trials have been performed in patients having liver 
transplantation; TXA did not result in significant reduction of allogenic blood transfusion, 
although the confidence interval was wide and there was a trend towards improvement.44  Only 
one randomized controlled trial has examined the role of perioperative parenteral TXA in 
patients undergoing liver resection.33 Among 212 patients who underwent liver resection, the 
blood transfusion rate was 16% in the control group and 0% in patients who received 
preoperative TXA (p < 0.001).  This trial included mainly patients undergoing minor liver 
resection, with only 18% of patients having major liver resection (greater than two segments), 
and the results have not changed practice in North America32. 
The trials included in the meta-analysis all evaluated the impact of TXA on clinical 
outcomes, but only a few of them examined the impact of TXA on laboratory measures of 
hemostasis.  In one trial of TXA in patients undergoing total hip arthroplasty with concomitant 
hydroxyethyl starch, patients randomized to the control group demonstrated significant 
fibrinolysis on TEG, and this effect was attenuated by TXA.45  Two trials have examined the 
impact of TXA on TEG markers of fibrinolysis in cardiac surgery, yielding conflicting 
conclusions.46, 47  To our knowledge, none of the trials identified measured the impact of TXA on 
PAP complex levels. 
 In our study, TXA did not impact the extent of fibrinolysis as measured with TEG or PAP 
complex levels.  It is possible that neither of these measures are sensitive enough to detect 
clinically relevant changes in fibrinolysis that TXA impacts.  Another possibility is that TXA acts 
through a different mechanism that is not accurately assessed by TEG or PAP complexes.  
Further research is warranted to elucidate the mechanism of action of TXA, and to investigate 
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the impact of other antifibrinolytic agents on the hemostatic system in this setting.  
Furthermore, given the compelling evidence of TXA’s effectiveness in other settings, trials 
examining the impact of TXA on clinical outcomes (bleeding and blood transfusion) following 
liver surgery would be beneficial. 
Our study provides pharmacokinetic information that may be used to design future 
trials of TXA in patients undergoing liver resection.  The two most commonly used doses of TXA 
are 1 g bolus followed by 1 g over 8 hours (from the CRASH-2 trial) and 1 g bolus followed by 10 
mg/kg/hr in liver transplantation studies.27,43  In a meta-regression analysis, the effectiveness of 
TXA was stable over a wide range of doses, suggesting that the impact of TXA is not dose-
dependent at the concentrations used clinically.  In contrast, more complications (most notably 
seizures) were observed at higher doses.  The plasma tranexamic acid concentration reported 
to inhibit fibrinolysis in vitro is 10 µg/mL in cardiac surgery.48   Thus, our study suggests that a 
dose of 1 g bolus followed by 1 g over 8 hours is sufficient to inhibit fibrinolysis in this setting. 
 This study is most limited by the relatively low sample size.  It was not powered to 
identify relationships between extent of fibrinolysis and clinical outcomes; although this would 
be an interesting area for future study.  We did not include a comparator group of patients 
undergoing other types of operations, so it is difficult to determine the impact of the liver 
resection on fibrinolysis compared with any other major operative interventions.   
In summary, this trial demonstrated no evidence of hyperfibrinolysis during liver 
resection by thromboelastography and only modest increases in PAP, a more sensitive marker 
of fibrinolysis.  Neither of these hemostatic parameters was altered by TXA, despite serum 
concentrations in excess of 10 mcg/ml; the concentration demonstrated in vitro to be required 
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to completely inhibit fibrinolysis.  Although there does not appear to be substantial systemic 
hyperfibrinolysis in patients undergoing major liver resection, there may be excessive 
fibrinolysis locally at the parenchymal surface, and inhibition of this process with TXA may 
strengthen clot.  Further research is warranted to elucidate the mechanism of action of TXA and 
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Tables 





TXA Dose I 
(6) 
TXA Dose II 
(6) 
Age, Median (IQR) 68 (61-73) 66 (63-69) 62 (54-68) 
K-W p-value 0.59 
Male, N (%) 4 (67) 3 (50) 3 (50) 
F-E p-value 1.00 
Weight – kg, Median (IQR) 76 (60-84) 82 (79-86) 62 (51-75) 
K-W p-value 0.20 
Diagnosis, N (%)     
   Colorectal Metastases 16 (89)  6  (100) 5 (83) 5 (83) 
   Hepatocellular Carcinoma 1 (6) 0 (0) 1 (17) 0 (0) 
   Cholangiocarcinoma 0 (0) 0 (0) 1 (17) 
F-E p-value 1.00 
Operation, N (%)     
   Extended Right Hepatectomy 5 (28) 2 (33) 1 (17) 2 (33) 
   Right Hepatectomy 4 (22) 1 (17) 2 (33) 1 (17) 
   Left Hepatectomy 1 (6) 0 (0) 0 (0) 1 (17) 
   Other 3 (50) 3 (50) 2 (33) 
F-E p-value 1.00 
Number of Segments Resected, 
Median (IQR) 
4 (4-4) 5 (3-5) 4 (3-5) 
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K-W p-value 0.87 








K-W p-value 0.32 
Parenchymal Transection Time – 
minutes, Median (IQR) 
60 (49-119) 93 (72-122) 64 (40-87) 
K-W p-value 0.54 
Inflow Occlusion (Pringle), N (%) 5 (83) 6 (100) 4 (67) 
F-E p-value 0.74 
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TXA Dose I- 
(6) 
TXA Dose II 
(6) 
Red Blood Cell Transfusion*, N (%) 0 (0) 1 (17) 0 (0) 
F-E p-value 1.00 
Complications, N (%)     
   Confusion 2 (11) 0 2 (33) 0 
   Fever 1 (6) 0 0 1 (17) 
   Ileus 1 (6) 0 1 (17) 0 
   Urinary 1 (6) 0 0 1 (17) 
   Ascites 1 (6) 0 1 (17) 0 
Length of Stay – days, 
Median (IQR) 
4 (4-4) 11 (4-15) 6 (4-15) 
K-W p-value 0.11 
Readmission, N (%) 0 0 2 
F-E p-value 0.29 
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Figure Legends 
Figure 1. Trend in INR values at different time points (error bars represent standard error).  
Dashed line represents upper limit of normal range (1.10). 
Figure 2. Trend in fibrinogen values at different time points (error bars represent standard 
error).  Dashed line represents lower limit of normal range (2 g/L). 
Figure 3. Trend in plasmin-antiplasmin (PAP) complex values at different time points (error bars 
represent standard error).  Dashed line represents upper limit of normal range (512 ug/L).  
Figure 4. Plasma concentration of TXA at different time points relative to bolus and infusion of 
TXA in patients (error bars represent standard error).  Dashed line represents in-vitro 
therapeutic level of TXA (10 µg/mL). 
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